Molecular Pharmacology Group, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Scotland, United Kingdom.
Curr Top Med Chem. 2013;13(1):14-25. doi: 10.2174/1568026611313010004.
G protein coupled receptors (GPCRs) are the most historically successful therapeutic targets. Despite this success there are many important aspects of GPCR pharmacology and function that have yet to be exploited to their full therapeutic potential. One in particular that has been gaining attention in recent times is that of GPCR ligands that bind to allosteric sites on the receptor distinct from the orthosteric site of the endogenous ligand. As therapeutics, allosteric ligands possess many theoretical advantages over their orthosteric counterparts, including more complex modes of action, improved safety, more physiologically appropriate responses, better target selectivity, and reduced likelihood of desensitisation and tachyphylaxis. Despite these advantages, the development of allosteric ligands is often difficult from a medicinal chemistry standpoint due to the more complex challenge of identifying allosteric leads and their often flat or confusing SAR. The present review will consider the advantages and challenges associated with allosteric GPCR ligands, and examine how the particular properties of these ligands may be exploited to uncover the therapeutic potential for free fatty acid sensitive GPCRs.
G 蛋白偶联受体(GPCRs)是历史上最成功的治疗靶点。尽管取得了这一成功,但 GPCR 药理学和功能仍有许多重要方面尚未被充分挖掘以发挥其全部治疗潜力。近年来,人们越来越关注与内源性配体的变构结合位点结合的 GPCR 配体。作为治疗剂,变构配体具有许多优于其变构对应物的理论优势,包括更复杂的作用模式、更高的安全性、更符合生理的反应、更好的靶标选择性以及降低脱敏和快速耐受的可能性。尽管有这些优势,但从药物化学的角度来看,变构配体的开发通常很困难,因为确定变构先导物及其通常平坦或混乱的 SAR 更具挑战性。本综述将考虑与变构 GPCR 配体相关的优势和挑战,并探讨如何利用这些配体的特殊性质来发现游离脂肪酸敏感 GPCR 的治疗潜力。